„DRACO“ – Versionsunterschied
Zur Navigation springen
Zur Suche springen
| [ungesichtete Version] | [ungesichtete Version] |
Inhalt gelöscht Inhalt hinzugefügt
Istvan (Diskussion | Beiträge) clean up links |
Istvan (Diskussion | Beiträge) add mechanism para and ref |
||
| Zeile 1: | Zeile 1: | ||
'''DRACO''' ("'''D'''ouble-stranded '''R'''NA (dsRNA) '''A'''ctivated '''C'''aspase '''O'''ligomerizer") is a group of experimental [[antiviral drug]]s under development at the [[Massachusetts Institute of Technology]]. DRACO is reported to have broad-spectrum efficacy against many types of infectious virii, including [[HIV]], [[Dengue virus|Dengue flavivirus]], Amapari and Tacaribe [[Arenavirus]], Guama [[Bunyaviridae|bunyavirus]], [[H1N1 influenza]] and [[rhinovirus]]. DRACO is reported to induce rapid [[apoptosis]] selectively in virus-infected mammalian cells, while leaving uninfected cells unharmed.<ref name="PLoS ONE |
'''DRACO''' ("'''D'''ouble-stranded '''R'''NA (dsRNA) '''A'''ctivated '''C'''aspase '''O'''ligomerizer") is a group of experimental [[antiviral drug]]s under development at the [[Massachusetts Institute of Technology]]. DRACO is reported to have broad-spectrum efficacy against many types of infectious virii, including [[HIV]], [[Dengue virus|Dengue flavivirus]], Amapari and Tacaribe [[Arenavirus]], Guama [[Bunyaviridae|bunyavirus]], [[H1N1 influenza]] and [[rhinovirus]]. DRACO is reported to induce rapid [[apoptosis]] selectively in virus-infected mammalian cells, while leaving uninfected cells unharmed.<ref name="PLoS ONE abstr">{{cite journal |author=Todd H. Rider*, Christina E. Zook, Tara L. Boettcher, Scott T. Wick, Jennifer S. Pancoast, Benjamin D. Zusman |title=Broad-Spectrum Antiviral Therapeutics|journal=PLoS ONE |year=2011 |month=July |url=http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0022572#abstract0}}</ref><ref name="Macrae">{{citation |url=http://http://www.dailymail.co.uk/health/article-2024492/Greatest-discovery-penicillin-Scientists-work-drug-cure-viruses--including-flu.html |title=Greatest discovery since penicillin: A cure for everything - from colds to HIV |work=The Daily Mail |location=UK | |author=Fiona Macrae | date=11 August 2011 }}</ref> |
||
==Mechanism== |
|||
DRACOs efficacy is selective for virus-infected cells. Differentiation between infected and healthy cells is made primarily via the length of RNA transcription helices present within the cell. Most viruses produce long dsRNA helices during transcription and replication. In contrast, uninfected mammalian cells generally produce dsRNA helices of less than 23 base pairs during transcription.<ref name="PLoS ONE intro">{{cite journal |author=Todd H. Rider*, Christina E. Zook, Tara L. Boettcher, Scott T. Wick, Jennifer S. Pancoast, Benjamin D. Zusman |title=Broad-Spectrum Antiviral Therapeutics|journal=PLoS ONE |year=2011 |month=July |url=http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0022572#s1}}</ref> |
|||
==References== |
==References== |
||
Version vom 11. August 2011, 06:16 Uhr
DRACO ("Double-stranded RNA (dsRNA) Activated Caspase Oligomerizer") is a group of experimental antiviral drugs under development at the Massachusetts Institute of Technology. DRACO is reported to have broad-spectrum efficacy against many types of infectious virii, including HIV, Dengue flavivirus, Amapari and Tacaribe Arenavirus, Guama bunyavirus, H1N1 influenza and rhinovirus. DRACO is reported to induce rapid apoptosis selectively in virus-infected mammalian cells, while leaving uninfected cells unharmed.[1][2]
Mechanism
DRACOs efficacy is selective for virus-infected cells. Differentiation between infected and healthy cells is made primarily via the length of RNA transcription helices present within the cell. Most viruses produce long dsRNA helices during transcription and replication. In contrast, uninfected mammalian cells generally produce dsRNA helices of less than 23 base pairs during transcription.[3]
References
- ↑ Todd H. Rider*, Christina E. Zook, Tara L. Boettcher, Scott T. Wick, Jennifer S. Pancoast, Benjamin D. Zusman: Broad-Spectrum Antiviral Therapeutics. In: PLoS ONE. Juli 2011 (plosone.org).
- ↑ Vorlage:Citation
- ↑ Todd H. Rider*, Christina E. Zook, Tara L. Boettcher, Scott T. Wick, Jennifer S. Pancoast, Benjamin D. Zusman: Broad-Spectrum Antiviral Therapeutics. In: PLoS ONE. Juli 2011 (plosone.org).